Fujirebio
Fujirebio Europe Picks up Distribution Rights to Self-screen's RUO Anal Cancer Assay
The assay is designed to detect promoter hypermethylation of the genes ASCL1 and ZNF582, a hallmark of HPV-induced cancer, for risk stratification of anal lesions.
New Products Posted to GenomeWeb: Illumina, Fujirebio, Tianlong, Telesis Bio, BioEcho Life Sciences
New products and services posted to GenomeWeb for the week of March 27, 2023.
Fujirebio Europe to Distribute Self-Screen Cervical Cancer Test
The test is designed to detect elevated methylation levels of cervical cancer biomarkers and may be used as a triage follow-up test of HPV-positive women.
Fujirebio Europe, Ohmx.bio Nab $873K Grant to Develop Clinical Third-Generation Sequencing Platform
The firms said that they will initially focus on the development of a portable, modular platform to detect highly polymorphic regions.
Morphotek, Fujirebio to Develop CA125 II Assay as CDx
The companies will validate and commercialize the assay as a companion diagnostic to identify best responders to Morphotek's investigational ovarian cancer treatment.
Oct 14, 2014
Oct 19, 2012
May 4, 2009
BD, Fujirebio Partner on Cancer Dx Assays
Feb 19, 2009
Industry Briefs: Feb 19, 2009
Premium
Feb 17, 2009